Introducing Large Genomic Deletions in Human Pluripotent Stem Cells Using CRISPR-Cas3.

Current Protocols Pub Date : 2022-02-01 DOI:10.1002/cpz1.361
Zhonggang Hou, Chunyi Hu, Ailong Ke, Yan Zhang
{"title":"Introducing Large Genomic Deletions in Human Pluripotent Stem Cells Using CRISPR-Cas3.","authors":"Zhonggang Hou,&nbsp;Chunyi Hu,&nbsp;Ailong Ke,&nbsp;Yan Zhang","doi":"10.1002/cpz1.361","DOIUrl":null,"url":null,"abstract":"<p><p>CRISPR-Cas systems provide researchers with eukaryotic genome editing tools and therapeutic platforms that make it possible to target disease mutations in somatic organs. Most of these tools employ Type II (e.g., Cas9) or Type V (e.g., Cas12a) CRISPR enzymes to create RNA-guided precise double-strand breaks in the genome. However, such technologies are limited in their capacity to make targeted large deletions. Recently, the Type I CRISPR system, which is prevalent in microbes and displays unique enzymatic features, has been harnessed to effectively create large chromosomal deletions in human cells. Type I CRISPR first uses a multisubunit ribonucleoprotein (RNP) complex called Cascade to find its guide-complementary target site, and then recruits a helicase-nuclease enzyme, Cas3, to travel along and shred the target DNA over a long distance with high processivity. When introduced into human cells as purified RNPs, the CRISPR-Cas3 complex can efficiently induce large genomic deletions of varying lengths (1-100 kb) from the CRISPR-targeted site. Because of this unique editing outcome, CRISPR-Cas3 holds great promise for tasks such as the removal of integrated viral genomes and the interrogation of structural variants affecting gene function and human disease. Here, we provide detailed protocols for introducing large deletions using CRISPR-Cas3. We describe step-by-step procedures for purifying the Type I-E CRISPR proteins Cascade and Cas3 from Thermobifida fusca, electroporating RNPs into human cells, and characterizing DNA deletions using PCR and sequencing. We focus here on human pluripotent stem cells due to their clinical potential, but these protocols will be broadly useful for other cell lines and model organisms for applications including large genomic deletion, full-gene or -chromosome removal, and CRISPR screening for noncoding elements, among others. © 2022 Wiley Periodicals LLC. Basic Protocol 1: Expression and purification of Tfu Cascade RNP Support Protocol 1: Expression and purification of TfuCas3 protein Support Protocol 2: Culture of human pluripotent stem cells Basic Protocol 2: Introduction of Tfu Cascade RNP and Cas3 protein into hPSCs via electroporation Basic Protocol 3: Characterization of genomic DNA lesions using long-range PCR, TOPO cloning, and Sanger sequencing Alternate Protocol: Comprehensive analysis of genomic lesions by Tn5-based next-generation sequencing Support Protocol 3: Single-cell clonal isolation.</p>","PeriodicalId":11174,"journal":{"name":"Current Protocols","volume":"2 2","pages":"e361"},"PeriodicalIF":0.0000,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843033/pdf/nihms-1770211.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Protocols","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/cpz1.361","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

CRISPR-Cas systems provide researchers with eukaryotic genome editing tools and therapeutic platforms that make it possible to target disease mutations in somatic organs. Most of these tools employ Type II (e.g., Cas9) or Type V (e.g., Cas12a) CRISPR enzymes to create RNA-guided precise double-strand breaks in the genome. However, such technologies are limited in their capacity to make targeted large deletions. Recently, the Type I CRISPR system, which is prevalent in microbes and displays unique enzymatic features, has been harnessed to effectively create large chromosomal deletions in human cells. Type I CRISPR first uses a multisubunit ribonucleoprotein (RNP) complex called Cascade to find its guide-complementary target site, and then recruits a helicase-nuclease enzyme, Cas3, to travel along and shred the target DNA over a long distance with high processivity. When introduced into human cells as purified RNPs, the CRISPR-Cas3 complex can efficiently induce large genomic deletions of varying lengths (1-100 kb) from the CRISPR-targeted site. Because of this unique editing outcome, CRISPR-Cas3 holds great promise for tasks such as the removal of integrated viral genomes and the interrogation of structural variants affecting gene function and human disease. Here, we provide detailed protocols for introducing large deletions using CRISPR-Cas3. We describe step-by-step procedures for purifying the Type I-E CRISPR proteins Cascade and Cas3 from Thermobifida fusca, electroporating RNPs into human cells, and characterizing DNA deletions using PCR and sequencing. We focus here on human pluripotent stem cells due to their clinical potential, but these protocols will be broadly useful for other cell lines and model organisms for applications including large genomic deletion, full-gene or -chromosome removal, and CRISPR screening for noncoding elements, among others. © 2022 Wiley Periodicals LLC. Basic Protocol 1: Expression and purification of Tfu Cascade RNP Support Protocol 1: Expression and purification of TfuCas3 protein Support Protocol 2: Culture of human pluripotent stem cells Basic Protocol 2: Introduction of Tfu Cascade RNP and Cas3 protein into hPSCs via electroporation Basic Protocol 3: Characterization of genomic DNA lesions using long-range PCR, TOPO cloning, and Sanger sequencing Alternate Protocol: Comprehensive analysis of genomic lesions by Tn5-based next-generation sequencing Support Protocol 3: Single-cell clonal isolation.

Abstract Image

利用CRISPR-Cas3在人类多能干细胞中引入大基因组缺失。
CRISPR-Cas系统为研究人员提供了真核基因组编辑工具和治疗平台,使其能够靶向体细胞器官中的疾病突变。这些工具大多使用II型(如Cas9)或V型(如Cas12a) CRISPR酶在基因组中创建rna引导的精确双链断裂。然而,这些技术在进行有针对性的大规模删除方面的能力有限。最近,在微生物中普遍存在的I型CRISPR系统显示出独特的酶特性,已被利用来有效地在人类细胞中产生大量的染色体缺失。I型CRISPR首先使用一种称为Cascade的多亚基核糖核蛋白(RNP)复合体来寻找其引导互补的靶点,然后招募一种解旋酶-核酸酶Cas3,以高加工速度沿着目标DNA行进并长距离切碎。当作为纯化的RNPs导入人类细胞时,CRISPR-Cas3复合物可以有效地从crispr靶向位点诱导不同长度(1-100 kb)的大基因组缺失。由于这种独特的编辑结果,CRISPR-Cas3在诸如去除整合病毒基因组和询问影响基因功能和人类疾病的结构变异等任务中具有很大的前景。在这里,我们提供了使用CRISPR-Cas3引入大缺失的详细协议。我们描述了从fusca Thermobifida中纯化I-E型CRISPR蛋白Cascade和Cas3的逐步过程,将RNPs电穿孔到人类细胞中,并使用PCR和测序表征DNA缺失。由于人类多能干细胞的临床潜力,我们将重点放在人类多能干细胞上,但这些方案将广泛应用于其他细胞系和模式生物,包括大基因组缺失,全基因或染色体去除,以及非编码元件的CRISPR筛选等。©2022 Wiley期刊有限责任公司基本方案1:Tfu级联RNP的表达和纯化支持方案1:TfuCas3蛋白的表达和纯化支持方案2:人多能干细胞培养基本方案2:通过电穿孔将Tfu级联RNP和Cas3蛋白引入hPSCs基本方案3:使用远程PCR、TOPO克隆和Sanger测序表征基因组DNA病变基于tn5的下一代测序对基因组病变的综合分析支持方案3:单细胞克隆分离。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信